142 related articles for article (PubMed ID: 7402434)
1. [3H]2-amino-6,7-dihydroxy-1,2,3,4-tetrahydronaphthalen (ADTN). Regional distribution and in vivo binding after acute and chronic drug treatment.
Clement-Cormier Y; Smith CE
Neurochem Res; 1980 Jun; 5(6):641-51. PubMed ID: 7402434
[TBL] [Abstract][Full Text] [Related]
2. Striatal binding of 2-amino-6,7-[3H]dihydroxy-1,2,3,4-tetrahydronaphthalene to two dopaminergic sites distinguished by their low and high affinity for neuroleptics.
List SJ; Wreggett KA; Seeman P
J Neurosci; 1982 Jul; 2(7):895-906. PubMed ID: 6124583
[TBL] [Abstract][Full Text] [Related]
3. Pharmacology of high-affinity binding of [3H](+/-)2-amino-6,7-dihydroxy-1,2,3,4-tetrahydronaphthalene (ADTN) to bovine caudate nucleus tissue.
Arana GW; Baldessarini RJ; Lamont JS; Amlicke D; Neumeyer JL
Biochem Pharmacol; 1983 Oct; 32(19):2873-80. PubMed ID: 6626260
[TBL] [Abstract][Full Text] [Related]
4. Similar binding of 3H-ADTN and 3H-apomorphine to calf brain dopamine receptors.
Seeman P; Woodruff GN; Poat JA
Eur J Pharmacol; 1979 Apr; 55(2):137-42. PubMed ID: 456412
[TBL] [Abstract][Full Text] [Related]
5. [3H] 2-Amino-6,7-dihydroxy 1,2,3,4-tetrahydronapthalene (ADTN): a potential specific dopamine receptor ligand.
Clement-Cormier Y; Abel M
Res Commun Chem Pathol Pharmacol; 1978 Oct; 22(1):15-25. PubMed ID: 725314
[TBL] [Abstract][Full Text] [Related]
6. Properties of dopamine agonist and antagonist binding sites in mammalian retina.
Makman MH; Dvorkin B; Horowitz SG; Thal LJ
Brain Res; 1980 Aug; 194(2):403-18. PubMed ID: 6770965
[TBL] [Abstract][Full Text] [Related]
7. Identification of dopamine "D3" and "D4" binding sites, labelled with [3H]2-amino-6,7-dihydroxy-1,2,3,4-tetrahydronaphthalene, as high agonist affinity states of the D1 and D2 dopamine receptors, respectively.
Urwyler S; Markstein R
J Neurochem; 1986 Apr; 46(4):1058-67. PubMed ID: 2936868
[TBL] [Abstract][Full Text] [Related]
8. Selective storage in vivo of 5,6-ADTN in dopamine-rich areas of the rat brain.
Westerink BH; Dijkstra D; Feenstra MG; Horn AS; Rollema H
Eur J Pharmacol; 1980 Jun; 64(2-3):115-21. PubMed ID: 7398758
[TBL] [Abstract][Full Text] [Related]
9. Effects of ADTN and various other 2-aminotetralin derivatives on the efflux of 3H-dopamine from rat striatal slices.
Mulder AH; Braakhuis B; De Regt V; Dijkstra D; Horn AS
Eur J Pharmacol; 1980 Jun; 64(4):349-55. PubMed ID: 7389827
[TBL] [Abstract][Full Text] [Related]
10. Changes in (3H)-ADTN binding to microsomal and synaptic membrane fractions from rat striata following kainic acid lesions.
Davis A; Woodruff GN; Poat JA; Freedman SB
Biochem Pharmacol; 1980 Jun; 29(12):1645-8. PubMed ID: 7406893
[No Abstract] [Full Text] [Related]
11. Effects of cations on high-affinity binding of 3H-ADTN to dopaminergic sites in calf caudate tissue.
Lamont JS; Kula NS; Baldessarini RJ
Neuropharmacology; 1987 Jun; 26(6):637-9. PubMed ID: 3601010
[TBL] [Abstract][Full Text] [Related]
12. S(-)DP-5,6-ADTN as an in vivo dopamine receptor ligand: relation between displacement by dopamine agonists and their pharmacological effects.
Rollema H; Feenstra MG; Grol CJ; Lewis MH; Staples L; Mailman RB
Naunyn Schmiedebergs Arch Pharmacol; 1986 Apr; 332(4):338-45. PubMed ID: 3736679
[TBL] [Abstract][Full Text] [Related]
13. Binding of [3H]ADTN to rat striatal membranes.
Templeton WW; Woodruff GN
Biochem Pharmacol; 1982 Apr; 31(8):1629-32. PubMed ID: 6124259
[TBL] [Abstract][Full Text] [Related]
14. Binding of 3H-ADTN, a dopamine agonist, to membranes of the bovine retina.
Osborne NN
Cell Mol Neurobiol; 1981 Jun; 1(2):167-74. PubMed ID: 7346167
[TBL] [Abstract][Full Text] [Related]
15. Lack of effects of fibrinogen degradation products on specific binding of [3H]spiroperidol and [3H]ADTN.
Buczko W; De Blasi A
Pol J Pharmacol Pharm; 1983; 35(1):45-7. PubMed ID: 6889186
[TBL] [Abstract][Full Text] [Related]
16. The significance of COMT activity in controlling dopamine agonist levels in brain and serum: studies with a prodrug and a metabolite of 6,7-ADTN.
Rollema H; Westerink BH; Mulder TB; Dijkstra D; Feenstra MG; Horn AS
Eur J Pharmacol; 1980 Jun; 64(4):313-23. PubMed ID: 7389825
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and dopaminergic activity of some halogenated mono- and dihydroxylated 2-aminotetralins.
Weinstock J; Gaitanopoulos DE; Oh HJ; Pfeiffer FR; Karash CB; Venslavsky JW; Sarau HM; Flaim KE; Hieble JP; Kaiser C
J Med Chem; 1986 Sep; 29(9):1615-27. PubMed ID: 2875183
[TBL] [Abstract][Full Text] [Related]
18. Differential effects of ascorbate and EDTA on high-affinity binding of 3H-apomorphine and 3H-ADTN to calf caudate membranes.
Arana GW; Baldessarini RJ; Kula NS
Neuropharmacology; 1982 Jun; 21(6):601-4. PubMed ID: 6810198
[TBL] [Abstract][Full Text] [Related]
19. 6,7-Dihydroxy-3-chromanamine: synthesis and pharmacological activity of an oxygen isostere of the dopamine agonist 6,7-dihydroxy-2-aminotetralin.
Horn AS; Kaptein B; Mulder TB; de Vries JB; Wynberg H
J Med Chem; 1984 Oct; 27(10):1340-3. PubMed ID: 6090664
[TBL] [Abstract][Full Text] [Related]
20. Altered characteristics of striatal [3H]ADTN binding following substantia nigra lesions.
Hirschhorn ID; Makman MH
Eur J Pharmacol; 1982 Sep; 83(1-2):61-7. PubMed ID: 7128701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
